{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:46:06Z","timestamp":1790084766361,"version":"4.0.1"},"reference-count":141,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular adverse effects of drugs have significant practical implications for patient management. While cardiovascular adverse effects have commonly been associated with oncologic therapeutics, a growing body of evidence suggests that non-oncologic medications can also be associated with significant cardiovascular harm. These adverse effects range from arrhythmias, conduction abnormalities, QT prolongation, heart failure, myocardial infarction, or structural cardiomyopathy. Non-oncologic drugs that have been implicated include antibiotics (e.g. macrolides, fluoroquinolones), antidiabetics (e.g. thiazolidinediones), non-steroidal anti-inflammatory drugs, drugs for gastrointestinal and urological conditions, and most importantly, cardiovascular drugs. In this narrative review, we focus on the most common non-oncologic drugs that cause cardiovascular adverse effects, their proposed underlying mechanisms with particular emphasis on their clinical manifestations and clinical implications for everyday cardiovascular practice.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvag007","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:47:53Z","timestamp":1769777273000},"page":"118-134","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-4076","authenticated-orcid":false,"given":"M Cecilia","family":"Bahit","sequence":"first","affiliation":[{"name":"Baim Institute for Clinical Research , 930 Commonwealth Ave, Boston, MA 02215 ,","place":["USA"]},{"name":"INECO Neurociencias , Rosario, Santa Fe, 2000 ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Agudo-Quilez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario Ram\u00f3n y Cajal , Madrid 28034, Espana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-3741","authenticated-orcid":false,"given":"Jose","family":"Zamorano","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario Ram\u00f3n y Cajal , Madrid 28034, Espana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-9125","authenticated-orcid":false,"given":"C Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"Baim Institute for Clinical Research , 930 Commonwealth Ave, Boston, MA 02215 ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA 02215 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026022706312970600_pvag007-B1","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"US emergency department visits for outpatient adverse drug events, 2013\u20132014","volume":"316","author":"Shehab","year":"2016","journal-title":"JAMA"},{"key":"2026022706312970600_pvag007-B2","article-title":"Hospital admissions due to adverse drug reactions and adverse drug events in older adults: a systematic review","volume":"54","author":"Cosgrove","year":"2025","journal-title":"Age Ageing"},{"key":"2026022706312970600_pvag007-B3","first-page":"100260","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina","year":"2021","journal-title":"Cell Rep Med"},{"key":"2026022706312970600_pvag007-B4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.therap.2023.10.008","article-title":"Drug-induced cardiac toxicity and adverse drug reactions: a narrative review","volume":"79","author":"Destere","year":"2024","journal-title":"Therapie"},{"key":"2026022706312970600_pvag007-B5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026022706312970600_pvag007-B6"},{"key":"2026022706312970600_pvag007-B7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2125.2000.00230.x","article-title":"CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system","volume":"50","author":"Ford","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"2026022706312970600_pvag007-B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"2026022706312970600_pvag007-B9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026022706312970600_pvag007-B10","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","article-title":"Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications","volume":"40","author":"Ferdinandy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026022706312970600_pvag007-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"key":"2026022706312970600_pvag007-B12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"2026022706312970600_pvag007-B13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.14503\/THIJ-13-3633","article-title":"Clozapine-induced myocarditis: recognizing a potentially fatal adverse reaction","volume":"42","author":"Hatton","year":"2015","journal-title":"Tex Heart Inst J"},{"key":"2026022706312970600_pvag007-B14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5694\/j.1326-5377.2009.tb02345.x","article-title":"Clozapine-induced cardiotoxicity: a clinical update","volume":"190","author":"Layland","year":"2009","journal-title":"Med J Aust"},{"key":"2026022706312970600_pvag007-B15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJM199708283370912","article-title":"Valvular heart disease associated with dexfenfluramine","volume":"337","author":"Cannistra","year":"1997","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-2143(98)90149-4","article-title":"Valve disease associated with chronic intake of fenfluramines","volume":"131","author":"Malak","year":"1998","journal-title":"J Lab Clin Med"},{"key":"2026022706312970600_pvag007-B17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.acvd.2013.02.003","article-title":"Drug-induced valvular heart disease: an update","volume":"106","author":"Andrejak","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"2026022706312970600_pvag007-B18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2045125311433580","article-title":"Antidepressants, metoprolol and the risk of bradycardia","volume":"2","author":"Kurdyak","year":"2012","journal-title":"Ther Adv Psychopharmacol"},{"key":"2026022706312970600_pvag007-B20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/01.JGP.0000204328.50105.b3","article-title":"Cardiovascular changes associated with venlafaxine in the treatment of late-life depression","volume":"14","author":"Johnson","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"2026022706312970600_pvag007-B21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4062\/biomolther.2015.033","article-title":"Cardiovascular safety pharmacology of sibutramine","volume":"23","author":"Yun","year":"2015","journal-title":"Biomol Ther (Seoul)"},{"key":"2026022706312970600_pvag007-B22","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ijcard.2008.06.017","article-title":"Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use","volume":"137","author":"Eroglu","year":"2009","journal-title":"Int J Cardiol"},{"key":"2026022706312970600_pvag007-B23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B24","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.hrthm.2011.07.015","article-title":"Propoxyphene-induced torsades de pointes","volume":"8","author":"Adler","year":"2011","journal-title":"Heart Rhythm"},{"key":"2026022706312970600_pvag007-B25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-783X-14-1-7","article-title":"Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation: results from a controlled clinical trial","volume":"14","author":"Wieneke","year":"2009","journal-title":"Eur J Med Res"},{"key":"2026022706312970600_pvag007-B26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1385\/COMP:32:2:94","article-title":"Pergolide-associated valvular heart disease","volume":"32","author":"Waller","year":"2006","journal-title":"Compr Ther"},{"key":"2026022706312970600_pvag007-B27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson\u2019s disease","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol"},{"key":"2026022706312970600_pvag007-B28","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B29","doi-asserted-by":"crossref","first-page":"e013398","DOI":"10.1136\/bmjopen-2016-013398","article-title":"Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study","volume":"7","author":"Berni","year":"2017","journal-title":"BMJ Open"},{"key":"2026022706312970600_pvag007-B30","doi-asserted-by":"crossref","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ"},{"key":"2026022706312970600_pvag007-B31","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0022-3565(24)38820-2","article-title":"Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics","volume":"296","author":"Anderson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2026022706312970600_pvag007-B32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/jcph.872","article-title":"Electrophysiological adverse effects of direct acting antivirals in patients with chronic hepatitis C","volume":"57","author":"Durante-Mangoni","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026022706312970600_pvag007-B33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"2026022706312970600_pvag007-B34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/mol.111.075135","article-title":"Molecular determinants of pentamidine-induced hERG trafficking inhibition","volume":"81","author":"Dennis","year":"2012","journal-title":"Mol Pharmacol"},{"key":"2026022706312970600_pvag007-B35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1124\/jpet.105.093393","article-title":"Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs","volume":"316","author":"Katchman","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2026022706312970600_pvag007-B36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.vascn.2014.09.005","article-title":"Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents","volume":"70","author":"Gibson","year":"2014","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2026022706312970600_pvag007-B37","first-page":"100","article-title":"Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study","volume":"3","author":"Sondergaard","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026022706312970600_pvag007-B38","doi-asserted-by":"crossref","first-page":"i4857","DOI":"10.1136\/bmj.i4857","article-title":"Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study","volume":"354","author":"Arf\u00e8","year":"2016","journal-title":"BMJ"},{"key":"2026022706312970600_pvag007-B39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1017\/S1481803500007508","article-title":"Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects","volume":"4","author":"Loewen","year":"2002","journal-title":"CJEM"},{"key":"2026022706312970600_pvag007-B40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B41","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B43","doi-asserted-by":"crossref","first-page":"iv37","DOI":"10.1093\/europace\/eum169","article-title":"Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias","volume":"9","author":"Shantsila","year":"2007","journal-title":"Europace"},{"key":"2026022706312970600_pvag007-B44","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11894-017-0593-6","article-title":"Prokinetics in the management of functional gastrointestinal disorders","volume":"19","author":"Quigley","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"2026022706312970600_pvag007-B46","first-page":"5040176","article-title":"Loperamide induced life threatening ventricular arrhythmia","volume":"2016","author":"Upadhyay","year":"2016","journal-title":"Case Rep Cardiol"},{"key":"2026022706312970600_pvag007-B47","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.japh.2016.11.011","article-title":"Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse","volume":"57","author":"Swank","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2026022706312970600_pvag007-B48","doi-asserted-by":"crossref","first-page":"e84890","DOI":"10.1371\/journal.pone.0084890","article-title":"Proton pump inhibitors and the risk of adverse cardiac events","volume":"8","author":"Juurlink","year":"2013","journal-title":"PLoS One"},{"key":"2026022706312970600_pvag007-B49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/hrt.74.1.53","article-title":"Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence","volume":"74","author":"Thomas","year":"1995","journal-title":"Br Heart J"},{"key":"2026022706312970600_pvag007-B50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.phrs.2009.05.008","article-title":"H1 antihistamine drug promethazine directly blocks hERG K+ channel","volume":"60","author":"Jo","year":"2009","journal-title":"Pharmacol Res"},{"key":"2026022706312970600_pvag007-B51","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1001\/jama.1990.03450210088038","article-title":"Torsades de pointes occurring in association with terfenadine use","volume":"264","author":"Monahan","year":"1990","journal-title":"JAMA"},{"key":"2026022706312970600_pvag007-B52","first-page":"126","article-title":"Diphenhydramine and QT prolongation: a rare cardiac side effect of a drug used in common practice","volume":"12","author":"Shah","year":"2015","journal-title":"J Cardiol Cases"},{"key":"2026022706312970600_pvag007-B53","doi-asserted-by":"crossref","first-page":"111478","DOI":"10.1016\/j.jclinepi.2024.111478","article-title":"The evidence base of the 10 most prescribed drugs in England, France, and the United States: a scoping review","volume":"174","author":"Fournier","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026022706312970600_pvag007-B54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","article-title":"Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis","volume":"42","author":"Gorelik","year":"2019","journal-title":"Drug Saf"},{"key":"2026022706312970600_pvag007-B55","first-page":"1285","article-title":"The 2023 Canadian cardiovascular society clinical practice update on management of the patient with a prolonged QT interval","volume":"39","author":"Davies","year":"2023","journal-title":"Can J Cardiol"},{"key":"2026022706312970600_pvag007-B56","doi-asserted-by":"crossref","first-page":"e008074","DOI":"10.1161\/JAHA.117.008074","article-title":"Estimated cardiac risk associated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities","volume":"7","author":"Polgreen","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026022706312970600_pvag007-B57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10840-007-9124-y","article-title":"Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors","volume":"18","author":"Kezerashvili","year":"2007","journal-title":"J Interv Card Electrophysiol"},{"key":"2026022706312970600_pvag007-B58","first-page":"30","article-title":"Azithromycin-induced QT prolongation in elderly patient","volume":"77","author":"Russo","year":"2006","journal-title":"Acta Biomed"},{"key":"2026022706312970600_pvag007-B59","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: a scientific statement from the American Heart Association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"2026022706312970600_pvag007-B60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","article-title":"Cardiotoxicity of antimalarial drugs","volume":"7","author":"White","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"2026022706312970600_pvag007-B61","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.41934","article-title":"American College of Rheumatology white paper on antimalarial cardiac toxicity","volume":"73","author":"Desmarais","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026022706312970600_pvag007-B62","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nrd1201","article-title":"Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective","volume":"2","author":"Lewis","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2026022706312970600_pvag007-B63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.redox.2017.06.011","article-title":"Azidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system","volume":"13","author":"Nomura","year":"2017","journal-title":"Redox Biol"},{"key":"2026022706312970600_pvag007-B64","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/jac\/dkae116","article-title":"Cardiometabolic health in people with HIV: expert consensus review","volume":"79","author":"Batteram","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026022706312970600_pvag007-B65","first-page":"831","article-title":"Selective COX-2 inhibitors, NSAIDs and cardiovascular events\u2014is celecoxib the safest choice?","volume":"3","author":"Howes","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2026022706312970600_pvag007-B66","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMp048286","article-title":"Failing the public health\u2014rofecoxib, Merck, and the FDA","volume":"351","author":"Topol","year":"2004","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/1-4020-5688-5_8","article-title":"A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAIDs","volume":"42","author":"Mason","year":"2007","journal-title":"Subcell Biochem"},{"key":"2026022706312970600_pvag007-B68","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/joim.13505","article-title":"Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials","volume":"292","author":"Stiller","year":"2022","journal-title":"J Intern Med"},{"key":"2026022706312970600_pvag007-B69","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"2026022706312970600_pvag007-B70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11239-008-0264-4","article-title":"Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis","volume":"27","author":"Gibson","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"2026022706312970600_pvag007-B71","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.113.004480","article-title":"Nonsteroidal anti-inflammatory drugs and the heart","volume":"129","author":"Patrono","year":"2014","journal-title":"Circulation"},{"key":"2026022706312970600_pvag007-B72","doi-asserted-by":"crossref","first-page":"R1751","DOI":"10.1152\/ajpregu.90985.2008","article-title":"Renal and cardiovascular characterization of COX-2 knockdown mice","volume":"296","author":"Seta","year":"2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026022706312970600_pvag007-B73","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248414531852","article-title":"Food and drug administration regulation of drugs that raise blood pressure","volume":"20","author":"Blankfield","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026022706312970600_pvag007-B75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/clc.22502","article-title":"Nonsteroidal anti-inflammatory drugs and risk of incident heart failure: a systematic review and meta-analysis of observational studies","volume":"39","author":"Ungprasert","year":"2016","journal-title":"Clin Cardiol"},{"key":"2026022706312970600_pvag007-B76","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026022706312970600_pvag007-B77","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement","volume":"327","author":"US Preventive Services Task Force","year":"2022","journal-title":"JAMA"},{"key":"2026022706312970600_pvag007-B78","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026022706312970600_pvag007-B79","doi-asserted-by":"crossref","first-page":"716648","DOI":"10.3389\/fped.2021.716648","article-title":"Cardiotoxicity in biological agent-targeted therapy for rheumatoid arthritis: ADR signal mining and analysis of Food and Drug Administration adverse event reporting system database","volume":"9","author":"Tang","year":"2021","journal-title":"Front Pediatr"},{"key":"2026022706312970600_pvag007-B80","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0735-1097(25)01903-5","article-title":"Are anti-TNF medications related to heart failure? A study of the FAERS database","volume":"85","author":"Al-Mabrouk","year":"2025","journal-title":"J Am Coll Caridiol"},{"key":"2026022706312970600_pvag007-B81","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/imt.13.10","article-title":"Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature","volume":"5","author":"Jain","year":"2013","journal-title":"Immunotherapy"},{"key":"2026022706312970600_pvag007-B82","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"2026022706312970600_pvag007-B83","first-page":"e261","article-title":"Correction to: drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"134","year":"2016","journal-title":"Circulation"},{"key":"2026022706312970600_pvag007-B84","doi-asserted-by":"crossref","first-page":"812631","DOI":"10.3389\/fcvm.2021.812631","article-title":"Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis","volume":"8","author":"Baoqi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026022706312970600_pvag007-B85","first-page":"e17938","article-title":"Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis","volume":"13","author":"Hussain","year":"2021","journal-title":"Cureus"},{"key":"2026022706312970600_pvag007-B86","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/med.21476","article-title":"Comprehensive review of cardiovascular toxicity of drugs and related agents","volume":"38","author":"Mlad\u011bnka","year":"2018","journal-title":"Med Res Rev"},{"key":"2026022706312970600_pvag007-B87","doi-asserted-by":"crossref","first-page":"1187100","DOI":"10.3389\/fcvm.2023.1187100","article-title":"The role of glucocorticoids in increasing cardiovascular risk","volume":"10","author":"Deng","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026022706312970600_pvag007-B88","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/dc07-0141","article-title":"Thiazolidinediones and heart failure: a teleo-analysis","volume":"30","author":"Singh","year":"2007","journal-title":"Diabetes Care"},{"key":"2026022706312970600_pvag007-B89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026022706312970600_pvag007-B90","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/pds.2165","article-title":"Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus","volume":"20","author":"Filion","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026022706312970600_pvag007-B91","doi-asserted-by":"crossref","first-page":"d1309","DOI":"10.1136\/bmj.d1309","article-title":"Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies","volume":"342","author":"Loke","year":"2011","journal-title":"BMJ"},{"key":"2026022706312970600_pvag007-B92","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"2026022706312970600_pvag007-B93","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","article-title":"Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial","volume":"31","author":"Komajda","year":"2010","journal-title":"Eur Heart J"},{"key":"2026022706312970600_pvag007-B94","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022706312970600_pvag007-B95","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"2026022706312970600_pvag007-B96","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/jat.4613","article-title":"Cytotoxicity and toxicoproteomics analysis of thiazolidinedione exposure in human-derived cardiomyocytes","volume":"44","author":"Al Sultan","year":"2024","journal-title":"J Appl Toxicol"},{"key":"2026022706312970600_pvag007-B97","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.clinthera.2014.10.009","article-title":"Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?","volume":"36","author":"Clifton","year":"2014","journal-title":"Clin Ther"},{"key":"2026022706312970600_pvag007-B98","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.312673","article-title":"Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials","volume":"122","author":"Packer","year":"2018","journal-title":"Circ Res"},{"key":"2026022706312970600_pvag007-B99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026022706312970600_pvag007-B100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ejhf.707","article-title":"Liraglutide in heart failure: caution is needed","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026022706312970600_pvag007-B101","first-page":"247","article-title":"Beta-blocker and calcium-channel blocker toxicity: current evidence on evaluation and management","volume":"13","author":"Goldfine","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026022706312970600_pvag007-B102","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.82.6.1954","article-title":"A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure","volume":"82","author":"Elkayam","year":"1990","journal-title":"Circulation"},{"key":"2026022706312970600_pvag007-B103","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group","volume":"335","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B104","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jchf.2013.04.004","article-title":"Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026022706312970600_pvag007-B105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM198808183190701","article-title":"The effect of diltiazem on mortality and reinfarction after myocardial infarction","volume":"319","author":"Multicenter Diltiazem Postinfarction Trial Research Group","year":"1988","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1081\/CLT-100100932","article-title":"Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity","volume":"38","author":"Love","year":"2000","journal-title":"J Toxicol Clin Toxicol"},{"key":"2026022706312970600_pvag007-B107","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41440-020-0449-6","article-title":"Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies","volume":"43","author":"Koracevic","year":"2020","journal-title":"Hypertens Res"},{"key":"2026022706312970600_pvag007-B108","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"2026022706312970600_pvag007-B109","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0735-1097(01)01534-0","article-title":"Doxazosin and congestive heart failure","volume":"38","author":"Messerli","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026022706312970600_pvag007-B110","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B111","first-page":"e56755","article-title":"A comprehensive review on unveiling the journey of digoxin: past, present, and future perspectives","volume":"16","author":"Khandelwal","year":"2024","journal-title":"Cureus"},{"key":"2026022706312970600_pvag007-B112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00567110","article-title":"Haemodynamic effects of intravenous disopyramide in heart failure","volume":"8","author":"Jensen","year":"1975","journal-title":"Eur J Clin Pharmacol"},{"key":"2026022706312970600_pvag007-B113","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198003133021106","article-title":"Congestive heart failure caused by oral disopyramide","volume":"302","author":"Podrid","year":"1980","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B114","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/clpt.1985.99","article-title":"Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation","volume":"37","author":"Jackson","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"2026022706312970600_pvag007-B115","doi-asserted-by":"crossref","first-page":"95B","DOI":"10.1016\/0002-9149(84)90510-1","article-title":"Effects of flecainide on ventricular function: clinical and experimental correlations","volume":"53","author":"Josephson","year":"1984","journal-title":"Am J Cardiol"},{"key":"2026022706312970600_pvag007-B116","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/oxfordjournals.eurheartj.a061918","article-title":"Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy","volume":"6","author":"Legrand","year":"1985","journal-title":"Eur Heart J"},{"key":"2026022706312970600_pvag007-B117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17431380410032445","article-title":"Drug-induced QT interval prolongation: regulatory perspectives and drug development","volume":"36","author":"Shah","year":"2004","journal-title":"Ann Med"},{"key":"2026022706312970600_pvag007-B118","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B119","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"Eur Thyroid J"},{"key":"2026022706312970600_pvag007-B120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15563650.2018.1497172","article-title":"Mechanisms of toxic cardiomyopathy","volume":"57","author":"Hantson","year":"2019","journal-title":"Clin Toxicol (Phila)"},{"key":"2026022706312970600_pvag007-B121","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molcel.2012.09.025","article-title":"Physiological roles of mitochondrial reactive oxygen species","volume":"48","author":"Sena","year":"2012","journal-title":"Mol Cell"},{"key":"2026022706312970600_pvag007-B122","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/17425255.1.4.655","article-title":"Drug-induced mitochondrial toxicity","volume":"1","author":"Chan","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026022706312970600_pvag007-B123","first-page":"Unit 2.15","article-title":"Current concepts in drug-induced mitochondrial toxicity","volume":"Chapter 2","author":"Nadanaciva","year":"2009","journal-title":"Curr Protoc Toxicol"},{"key":"2026022706312970600_pvag007-B124","first-page":"25.4.1","article-title":"Identifying compounds that induce opening of the mitochondrial permeability transition pore in isolated rat liver mitochondria","volume":"60","author":"Marroquin","year":"2014","journal-title":"Curr Protoc Toxicol"},{"key":"2026022706312970600_pvag007-B125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurheartj\/11.suppl_C.8","article-title":"Abnormal intracellular calcium handling in acute and chronic heart failure: role in systolic and diastolic dysfunction","volume":"11","author":"Perreault","year":"1990","journal-title":"Eur Heart J"},{"key":"2026022706312970600_pvag007-B126","doi-asserted-by":"crossref","first-page":"8416763","DOI":"10.1155\/2017\/8416763","article-title":"Oxidative stress: harms and benefits for human health","volume":"2017","author":"Pizzino","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"2026022706312970600_pvag007-B127","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/hrt.2006.088203","article-title":"Cell death in the cardiovascular system","volume":"93","author":"Clarke","year":"2007","journal-title":"Heart"},{"key":"2026022706312970600_pvag007-B128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1573403X12666160301120217","article-title":"Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias","volume":"12","author":"Cubeddu","year":"2016","journal-title":"Curr Cardiol Rev"},{"key":"2026022706312970600_pvag007-B129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med Res Rev"},{"key":"2026022706312970600_pvag007-B130","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J Clin Med"},{"key":"2026022706312970600_pvag007-B131","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026022706312970600_pvag007-B132","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/bcp.14752","article-title":"Drug-induced peripheral oedema: an aetiology-based review","volume":"87","author":"Largeau","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026022706312970600_pvag007-B133","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ecl.2019.08.013","article-title":"Drug-induced hypertension","volume":"48","author":"Foy","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2026022706312970600_pvag007-B134","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya","year":"2009","journal-title":"Lancet"},{"key":"2026022706312970600_pvag007-B135","doi-asserted-by":"crossref","first-page":"euaf076","DOI":"10.1093\/europace\/euaf076","article-title":"Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology","volume":"27","author":"Merino","year":"2025","journal-title":"Europace"},{"key":"2026022706312970600_pvag007-B136","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41397-024-00326-1","article-title":"A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care","volume":"24","author":"Chenchula","year":"2024","journal-title":"Pharmacogenomics"},{"key":"2026022706312970600_pvag007-B137","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41431-025-01950-6","article-title":"Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions","volume":"34","author":"Omran","year":"2025","journal-title":"Eur J Hum Genet"},{"key":"2026022706312970600_pvag007-B138","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharamacol Ther"},{"key":"2026022706312970600_pvag007-B139","doi-asserted-by":"crossref","first-page":"e024338","DOI":"10.1161\/JAHA.122.024338","article-title":"Clinician responses to a clinical decision support advisory for high risk of torsades de pointes","volume":"11","author":"Gallo","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026022706312970600_pvag007-B140","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jacep.2024.01.022","article-title":"QTNet: predicting drug-induced QT prolongation with artificial intelligence-enabled electrocardiograms","volume":"10","author":"Zhang","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"2026022706312970600_pvag007-B141","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/CIRCOUTCOMES.113.000651","article-title":"Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients","volume":"7","author":"Tisdale","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag007\/66709323\/pvag007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/118\/66709323\/pvag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/118\/66709323\/pvag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:31:53Z","timestamp":1772191913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/2\/118\/8455021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag007","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]}}}